Jefferies has initiated a ‘Buy’ rating on Sagility, setting a target price of ₹52, indicating an 18% upside from the current market price (CMP) of ₹43.91.
The brokerage highlights Sagility’s position as a leading BPM firm focused on the US healthcare sector and its potential to deliver double-digit revenue growth. Jefferies expects normalization of D&A costs and deleveraging to spur EPS growth.
Over FY25-27, the company is projected to deliver a 12% CAGR in revenue and a 40% CAGR in PAT, supported by its strong business fundamentals and superior earnings outlook.
Jefferies believes Sagility’s growth potential will sustain its current PE multiples, making it a compelling investment opportunity.
Disclaimer: The above is for informational purposes only. Please consult a financial advisor before making any investment decisions.
